#USA #Milan #pharmaceutical #Cambrex #R&D Facility

Cambrex Milan Celebrates 80 Years with New Facility

On August 11, 2026, Cambrex, a leading global contract development and manufacturing organization (CDMO), officially announced the commencement of construction on a state-of-the-art research and development facility at its Milan site. This significant investment of $30 million aims to broaden capabilities in advanced analytical methods and process research, alongside modernizing existing production facilities. With this expansion, Cambrex underscores its commitment to supporting the pharmaceutical industry in the development of complex small-molecule active ingredients.

This upgrade to the Milan R&D location is projected to be completed in the latter half of 2027. To meet the anticipated growth and rising demand for CDMO services, Cambrex has also acquired additional land adjacent to the site, thereby securing resources for future expansion and innovation in the years to come.

This year marks the 80th anniversary of Cambrex Profarmico Milano, a facility renowned for its longstanding tradition in supporting pharmaceutical development and manufacturing to its global clientele. The Milan team recently gathered to commemorate this milestone and to reflect on eight decades of scientific achievements and dedication to advancing human health.

Claudio Russolo, Chief Operating Officer at Cambrex, expressed, "The groundbreaking for this new facility is a testament to the enduring legacy and expertise of our Milan team. For 80 years, this location has been a cornerstone of pharmaceutical production in Europe. This expansion not only represents an investment in new technologies and capabilities but also in the future of our employees and our partners."

The investment builds upon Cambrex’s rich history of scientific expertise and high-quality manufacturing capabilities, positioning the company for its next chapter of growth. By enhancing its R&D capabilities in Milan, Cambrex strengthens its ability to meet the increasing complexity of today's therapies involving small-molecule drugs.

About Cambrex

Cambrex is a leading global CDMO that offers comprehensive services in the development and manufacturing of active pharmaceutical ingredients (APIs) throughout the entire lifecycle of a drug, as well as extensive analytical services. With over 45 years of experience and a team of 2,000 professionals serving clients across North America and Europe, Cambrex provides a wide array of specialized technologies and capabilities in API manufacturing including continuous flow processes, controlled substances, peptide synthesis, solid-state chemistry, biocatalysis, material characterization, complex synthesis, and highly potent APIs.